其他
速递 | 基因疗法治疗DMD，Sarepta/罗氏启动全球性临床试验
▎药明康德内容团队编辑
参考资料：
[1] Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy. Retrieved October 4, 2021, from https://www.globenewswire.com/news-release/2021/10/04/2307760/36419/en/Sarepta-Therapeutics-Announces-Initiation-of-EMBARK-a-Global-Pivotal-Study-of-SRP-9001-a-Gene-Therapy-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
[2] Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material https://investorrelations.sarepta.com/static-files/09358a6f-98f9-4e11-a59e-db6b0d0f584f
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。